Client News

RedHill Biopharma’s Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

Invitation to InflaRx Virtual R&D event on Vilobelimab for the Treatment of Hidradenitis Suppurativa

Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis

Temedica Introduces Permea: First Analytics Platform Integrating Patient-Generated Health Data

Creative Balloons appoints David Johnson as Chairman of the Board of Directors

EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus

Atriva Therapeutics receives U.S. FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections

Adocia announces its financial calendar for 2022

InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa